Protocol Ledger

NCT04472598 · Phase III · COMPLETED

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

Interventional Phase III clinical trial protocol NCT04472598 sponsored by AbbVie in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-29 Enrollment: 252 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04472598
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)252 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04472598
Protocol FieldVerified Registry Value
NCT IdentifierNCT04472598
Consolidated Lead SponsorAbbVie
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment252 participants (ACTUAL)
Registered Start Date2020-09-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI